Genomic correlates of response to immune checkpoint carcinoma

Citation Report

#	ARTICLE	IF	CITATIONS
1	Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers. Nature Communications, 2018, 9, 1317.	5.8	94
2	The Immune Landscape of Cancer. Immunity, 2018, 48, 812-830.e14.	6.6	3,706
3	First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. European Urology, 2018, 74, 309-321.	0.9	51
4	Chromatin regulation and immune escape. Science, 2018, 359, 745-746.	6.0	10
5	Clear cell carcinomas of the ovary and kidney: clarity through genomics. Journal of Pathology, 2018, 244, 550-564.	2.1	41
6	Epigenetic modifiers as new immunomodulatory therapies in solid tumours. Annals of Oncology, 2018, 29, 812-824.	0.6	73
7	PBRM1 loss promotes tumour response to immunotherapy. Nature Reviews Nephrology, 2018, 14, 142-142.	4.1	1
8	PBRM1 loss promotes tumour response to immunotherapy. Nature Reviews Clinical Oncology, 2018, 15, 134-135.	12.5	6
9	A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing. Science, 2018, 359, 770-775.	6.0	641
10	Next generation of immune checkpoint therapy in cancer: new developments and challenges. Journal of Hematology and Oncology, 2018, 11, 39.	6.9	597
11	Prognostic factors and prognostic models for renal cell carcinoma: a literature review. World Journal of Urology, 2018, 36, 1943-1952.	1.2	162
12	Non–Clear Cell Renal Cell Carcinomas: From Shadow to Light. Journal of Clinical Oncology, 2018, 36, 3624-3631.	0.8	42
13	Personalized Management of Advanced Kidney Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 330-341.	1.8	25
14	Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. Journal of Clinical Oncology, 2018, 36, 3553-3559.	0.8	49
15	Chromosome 3p Loss–Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology, 2018, 36, 3533-3539.	0.8	99
16	Progress in Kidney Cancer Outcomes Through Collaboration, Innovation, and Discovery. Journal of Clinical Oncology, 2018, 36, 3529-3532.	0.8	0
17	Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. Journal of Clinical Oncology, 2018, 36, 3353-3360.	0.8	474
18	Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment. Translational Gastroenterology and Hepatology, 2018, 3, 89-89.	1.5	30

#	Article	IF	Citations
19	Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and clinicians. Translational Lung Cancer Research, 2018, 7, 703-715.	1.3	152
20	Tumor mutational burden as predictive factor of response to immunotherapy. Translational Lung Cancer Research, 2018, 7, S358-S361.	1.3	8
21	Complete and Prolonged Response of Renal Cell Carcinoma With Rhabdoid Features to Checkpoint Inhibitor Therapy. Journal of Immunotherapy, 2018, 41, 340-342.	1.2	4
23	Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer. IScience, 2018, 9, 258-277.	1.9	83
24	Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities. Journal of Experimental Medicine, 2018, 215, 3115-3135.	4.2	29
25	Epigenetic Heterogeneity in Human Colorectal Tumors Reveals Preferential Conservation And Evidence of Immune Surveillance. Scientific Reports, 2018, 8, 17292.	1.6	17
26	Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders. , 2018, 6, 159.		56
27	Cancer research in the era of immunogenomics. ESMO Open, 2018, 3, e000475.	2.0	14
28	Progress of immune checkpoint therapy in the clinic (Review). Oncology Reports, 2019, 41, 3-14.	1.2	24
29	Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. Genome Medicine, 2018, 10, 93.	3.6	121
30	Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. PLoS Genetics, 2018, 14, e1007679.	1.5	14
31	Immediate Progressive Disease in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: a Multi-Institution Retrospective Study. Targeted Oncology, 2018, 13, 611-619.	1.7	3
32	Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy. Trends in Biochemical Sciences, 2018, 43, 1014-1032.	3.7	151
33	Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences. Frontiers in Pharmacology, 2018, 9, 1050.	1.6	48
36	Kidney cancer: The next decade. Journal of Experimental Medicine, 2018, 215, 2477-2479.	4.2	125
37	Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma. Drugs, 2018, 78, 1443-1457.	4.9	70
38	The hallmarks of successful anticancer immunotherapy. Science Translational Medicine, 2018, 10, .	5.8	419
39	Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. Journal of Molecular Biology, 2018, 430, 2014-2029.	2.0	42

#	Article	IF	Citations
40	The Role of DNA Methylation in Renal Cell Carcinoma. Molecular Diagnosis and Therapy, 2018, 22, 431-442.	1.6	46
41	Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms. Mammalian Genome, 2018, 29, 866-878.	1.0	10
42	Genetic and metabolic hallmarks of clear cell renal cell carcinoma. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1870, 23-31.	3.3	92
43	Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nature Medicine, 2018, 24, 1143-1150.	15.2	212
44	SWI/SNF Complexes in Ovarian Cancer: Mechanistic Insights and Therapeutic Implications. Molecular Cancer Research, 2018, 16, 1819-1825.	1.5	32
45	Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. Nature Reviews Clinical Oncology, 2018, 15, 639-650.	12.5	152
46	Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment. Biomedicines, 2018, 6, 26.	1.4	16
47	PBRM1 bromodomains variably influence nucleosome interactions and cellular function. Journal of Biological Chemistry, 2018, 293, 13592-13603.	1.6	33
48	Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591877742.	1.4	7
49	Transcriptional control of kidney cancer. Science, 2018, 361, 226-227.	6.0	9
50	Epigenetic modifiers: activities in renal cell carcinoma. Nature Reviews Urology, 2018, 15, 599-614.	1.9	68
51	Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. Cancer Treatment Reviews, 2018, 70, 127-137.	3.4	276
52	ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nature Medicine, 2018, 24, 556-562.	15.2	372
53	Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell Carcinoma. Cancer Journal (Sudbury, Mass), 2018, 24, 171-179.	1.0	18
54	Pan-cancer deconvolution of tumour composition using DNA methylation. Nature Communications, 2018, 9, 3220.	5.8	205
55	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nature Genetics, 2018, 50, 1271-1281.	9.4	438
56	Genomics and clinical correlates of renal cell carcinoma. World Journal of Urology, 2018, 36, 1899-1911.	1.2	32
57	Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discovery, 2018, 8, 1069-1086.	7.7	2,128

#	Article	IF	Citations
58	MiR-532-5p suppresses renal cancer cell proliferation by disrupting the ETS1-mediated positive feedback loop with the KRAS-NAP1L1/P-ERK axis. British Journal of Cancer, 2018, 119, 591-604.	2.9	63
59	Checkpoint blockade–based immunotherapy in the context of tumor microenvironment: Opportunities and challenges. Cancer Medicine, 2018, 7, 4517-4529.	1.3	34
60	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine, 2018, 24, 749-757.	15.2	900
61	Tracing Renal Cell Carcinomas back to the Nephron. Trends in Cancer, 2018, 4, 472-484.	3.8	17
62	Identification of an immune gene expression signature associated with favorable clinical features in Treg-enriched patient tumor samples. Npj Genomic Medicine, 2018, 3, 14.	1.7	33
63	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real–world results from an expanded access programme. BJU International, 2019, 123, 98-105.	1.3	70
64	Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target. Journal of Medical Genetics, 2019, 56, 43-49.	1.5	49
65	Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 485-495.	1.4	3
66	Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients. Clinical Cancer Research, 2019, 25, 957-966.	3.2	37
67	Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma. Clinical Cancer Research, 2019, 25, 6511-6523.	3.2	62
68	<i>ARID1A</i> knockdown triggers epithelial–mesenchymal transition and carcinogenesis features of renal cells: role in renal cell carcinoma. FASEB Journal, 2019, 33, 12226-12239.	0.2	30
69	Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors. Advances in Therapy, 2019, 36, 2638-2678.	1.3	145
70	Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation. Clinical Genitourinary Cancer, 2019, 17, e909-e912.	0.9	1
71	Role of tumor gene mutations in treatment response to immune checkpoint blockades. Precision Clinical Medicine, 2019, 2, 100-109.	1.3	11
72	HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer. Cancer Research, 2019, 79, 5482-5489.	0.4	86
73	Possible Biomarkers for Cancer Immunotherapy. Cancers, 2019, 11, 935.	1.7	35
75	The immune response–related mutational signatures and driver genes in non–small–cell lung cancer. Cancer Science, 2019, 110, 2348-2356.	1.7	86
76	Poly Combs the Immune System: PRC2 Loss in Malignant Peripheral Nerve Sheath Tumors Can Dampen Immune Responses. Cancer Research, 2019, 79, 3172-3173.	0.4	0

#	Article	IF	Citations
77	Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression. Nature Medicine, 2019, 25, 1073-1081.	15.2	125
78	Systematic review and REMARK scoring of renal cell carcinoma prognostic circulating biomarker manuscripts. PLoS ONE, 2019, 14, e0222359.	1.1	9
79	Targeted Therapies Following First-Line Immune Checkpoint Inhibitor Combination in Metastatic Renal Cell Carcinoma: A Single Center Experience. Kidney Cancer, 2019, 3, 171-176.	0.2	3
80	Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration. Cell Reports, 2019, 29, 2338-2354.e7.	2.9	74
81	Clonally Expanded T Cells Reveal Immunogenicity of Rhabdoid Tumors. Cancer Cell, 2019, 36, 597-612.e8.	7.7	100
82	Heat-Shock Protein 90 Controls the Expression of Cell-Cycle Genes by Stabilizing Metazoan-Specific Host-Cell Factor HCFC1. Cell Reports, 2019, 29, 1645-1659.e9.	2.9	22
83	Vascular endothelial growth factor and programmed death‑1 pathway inhibitors in renal cell carcinoma. Cancer, 2019, 125, 4148-4157.	2.0	21
84	Exceptionally rapid response to pembrolizumab in a SMARCA4‑deficient thoracic sarcoma overexpressing PD‑L1: A case report. Thoracic Cancer, 2019, 10, 2312-2315.	0.8	66
85	Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden. Lung Cancer, 2019, 138, 35-42.	0.9	53
86	Lack of clinical activity with crizotinib in a patient with FUS rearranged rhabdomyosarcoma with ALK protein overexpression. Pathology, 2019, 51, 655-657.	0.3	16
87	Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies. Genes and Diseases, 2019, 6, 232-246.	1.5	44
88	Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. BMC Cancer, 2019, 19, 857.	1.1	88
89	Cell death-related molecules and biomarkers for renal cell carcinoma targeted therapy. Cancer Cell International, 2019, 19, 221.	1.8	25
90	Clinical Validation of <i>PBRM1</i> Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma. JAMA Oncology, 2019, 5, 1631.	3.4	166
91	UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma. Cell, 2019, 179, 219-235.e21.	13.5	270
92	Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma. Cancer Discovery, 2019, 9, 1349-1357.	7.7	226
93	The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. Journal of Clinical Medicine, 2019, 8, 1534.	1.0	41
94	Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 924-931.	0.8	42

#	Article	IF	Citations
95	Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma. Neoplasia, 2019, 21, 247-256.	2.3	55
96	Implementing TMB measurement in clinical practice: considerations on assay requirements. ESMO Open, 2019, 4, e000442.	2.0	257
97	SWI/SNF Complex-Deficient Soft Tissue Neoplasms. Surgical Pathology Clinics, 2019, 12, 149-163.	0.7	42
98	T-cell receptor V and J usage paired with specific HLA alleles associates with distinct cervical cancer survival rates. Human Immunology, 2019, 80, 237-242.	1.2	16
99	Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma. Clinical Genitourinary Cancer, 2019, 17, e454-e460.	0.9	14
100	Dangerous liaisons: interplay between SWI/SNF, NuRD, and Polycomb in chromatin regulation and cancer. Genes and Development, 2019, 33, 936-959.	2.7	127
101	Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repairâ€"Deficient Colorectal Cancer. Cancer Immunology Research, 2019, 7, 1230-1236.	1.6	59
102	Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers. Cancer Discovery, 2019, 9, 1022-1035.	7.7	184
103	Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth. Cancer Immunology Research, 2019, 7, 1091-1105.	1.6	153
104	The m6A-suppressed P2RX6 activation promotes renal cancer cells migration and invasion through ATP-induced Ca2+ influx modulating ERK1/2 phosphorylation and MMP9 signaling pathway. Journal of Experimental and Clinical Cancer Research, 2019, 38, 233.	3.5	82
105	Î²-Catenin Activation Promotes Immune Escape and Resistance to Antiâ€"PD-1 Therapy in Hepatocellular Carcinoma. Cancer Discovery, 2019, 9, 1124-1141.	7.7	498
106	Retinoblastoma Inactivation Induces a Protumoral Microenvironment via Enhanced CCL2 Secretion. Cancer Research, 2019, 79, 3903-3915.	0.4	68
107	The current state of molecular testing in the treatment of patients with solid tumors, 2019. Ca-A Cancer Journal for Clinicians, 2019, 69, 305-343.	157.7	203
108	Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor. Annals of Oncology, 2019, 30, 1401-1403.	0.6	72
109	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. , 2019, 7, 131.		64
110	TUSC3 as a potential biomarker for prognosis in clear cell renal cell carcinoma. Oncology Letters, 2019, 17, 5073-5079.	0.8	3
111	Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade. Pharmacological Research, 2019, 145, 104258.	3.1	115
112	Pharmacological Modulation of Transcriptional Coregulators in Cancer. Trends in Pharmacological Sciences, 2019, 40, 388-402.	4.0	9

#	ARTICLE	IF	CITATIONS
113	Going to extremes: determinants of extraordinary response and survival in patients with cancer. Nature Reviews Cancer, 2019, 19, 339-348.	12.8	35
114	Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors. Expert Review of Molecular Diagnostics, 2019, 19, 517-529.	1.5	15
115	Whole-Exome Sequencing Identifies Somatic Mutations Associated With Mortality in Metastatic Clear Cell Kidney Carcinoma. Frontiers in Genetics, 2019, 10, 439.	1.1	18
116	The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma. OncoImmunology, 2019, 8, 1608132.	2.1	37
117	PBRM1 Regulates Stress Response in Epithelial Cells. IScience, 2019, 15, 196-210.	1.9	24
118	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 147-164.	1.8	459
119	Remodeling the cancer epigenome: mutations in the SWI/SNF complex offer new therapeutic opportunities. Expert Review of Anticancer Therapy, 2019, 19, 375-391.	1.1	30
120	Real-World Outcomes of Nivolumab and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Current Oncology, 2019, 26, 175-179.	0.9	23
121	Towards individualized therapy for metastatic renal cell carcinoma. Nature Reviews Clinical Oncology, 2019, 16, 621-633.	12.5	148
122	JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management. Modern Pathology, 2019, 32, 1344-1358.	2.9	49
123	The role of immune infiltrates as prognostic biomarkers in patients with breast cancer. Cancer Immunology, Immunotherapy, 2019, 68, 1671-1680.	2.0	56
124	TISIDB: an integrated repository portal for tumor–immune system interactions. Bioinformatics, 2019, 35, 4200-4202.	1.8	1,281
125	Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance. Liver International, 2019, 39, 43-62.	1.9	54
126	von Hippel-Lindau mutants in renal cell carcinoma are regulated by increased expression of RSUME. Cell Death and Disease, 2019, 10, 266.	2.7	15
127	Genomic correlates of response to immune checkpoint blockade. Nature Medicine, 2019, 25, 389-402.	15.2	346
128	Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes. Clinical Cancer Research, 2019, 25, 4592-4602.	3.2	447
129	Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response. Journal of Physical Education and Sports Management, 2019, 5, a003566.	0.5	6
130	Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy. Immunotherapy, 2019, 11, 515-529.	1.0	17

#	Article	IF	Citations
131	Current status of prognostic factors in patients with metastatic renal cell carcinoma. International Journal of Urology, 2019, 26, 608-617.	0.5	19
132	Successful treatment with nivolumab for SMARCA4â€deficient nonâ€small cell lung carcinoma with a high tumor mutation burden: A case report. Thoracic Cancer, 2019, 10, 1285-1288.	0.8	58
133	Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma. Genome Medicine, 2019, 11, 18.	3.6	36
134	The prognostic landscape of interactive biological processes presents treatment responses in cancer. EBioMedicine, 2019, 41, 120-133.	2.7	6
135	Overview of current and future systemic therapy for metastatic renal cell carcinoma. Japanese Journal of Clinical Oncology, 2019, 49, 395-403.	0.6	38
136	Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. Investigational New Drugs, 2019, 37, 1198-1206.	1.2	11
137	Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trialâ€"Clinical outcomes and molecular determinants of response. PLoS ONE, 2019, 14, e0210891.	1.1	13
138	The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nature Reviews Cancer, 2019, 19, 133-150.	12.8	1,657
139	Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma. Clinical Genitourinary Cancer, 2019, 17, e513-e521.	0.9	31
140	Immune Checkpoint Inhibition, the Key to Success in Renal Cell Carcinoma?. Kidney Cancer, 2019, 3, 199-211.	0.2	0
141	The Emerging Roles of ATP-Dependent Chromatin Remodeling Complexes in Pancreatic Cancer. Cancers, 2019, 11, 1859.	1.7	26
142	The evolving role of cytoreductive nephrectomy. Current Opinion in Urology, 2019, 29, 531-539.	0.9	1
143	The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy. Nature Genetics, 2019, 51, 1645-1651.	9.4	171
144	When Cold Is Hot: Immune Checkpoint Inhibition Therapy for Rhabdoid Tumors. Cancer Cell, 2019, 36, 575-576.	7.7	10
145	MELK is Upregulated in Advanced Clear Cell Renal Cell Carcinoma and Promotes Disease Progression by Phosphorylating PRAS40. Cell Transplantation, 2019, 28, 37S-50S.	1.2	16
146	High affinity binding of H3K14ac through collaboration of bromodomains 2, 4 and 5 is critical for the molecular and tumor suppressor functions of PBRM1. Molecular Oncology, 2019, 13, 811-828.	2.1	22
147	Radiogenomics in Clear Cell Renal Cell Carcinoma: Machine Learningâ€"Based High-Dimensional Quantitative CT Texture Analysis in Predicting *PBRM1* Mutation Status. American Journal of Roentgenology, 2019, 212, W55-W63.	1.0	83
148	Clear cell renal cell carcinoma with wildâ€type *von Hippelâ€Lindau* gene: a nonâ€existent or new tumour entity?. Histopathology, 2019, 74, 60-67.	1.6	27

#	ARTICLE	IF	CITATIONS
149	Neural regulation of drug resistance in cancer treatment. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 20-28.	3.3	8
150	Tumor cell heterogeneity and resistance; report from the 2018 Coffey–Holden Prostate Cancer Academy Meeting. Prostate, 2019, 79, 244-258.	1.2	13
151	Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions. European Urology, 2019, 75, 100-110.	0.9	178
152	Finding an Immunologic Beachhead in the Prostate Cancer Microenvironment. Journal of the National Cancer Institute, 2019, 111, 219-220.	3.0	10
153	The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced–stage cancer treated with immunotherapy. Cancer, 2019, 125, 127-134.	2.0	120
154	Predictors of disease aggressiveness influence outcome from immunotherapy treatment in renal clear cell carcinoma. OncoImmunology, 2019, 8, e1500106.	2.1	18
155	Mechanisms of Resistance to Immune Checkpoint Blockade. American Journal of Clinical Dermatology, 2019, 20, 41-54.	3.3	83
156	Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion. European Urology, 2019, 75, 752-763.	0.9	123
157	Radiogenomics in renal cell carcinoma. Abdominal Radiology, 2019, 44, 1990-1998.	1.0	37
158	Mutations in renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 763-773.	0.8	58
159	State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era. European Urology Focus, 2020, 6, 37-40.	1.6	6
160	Exploiting epigenetic vulnerabilities in solid tumors: Novel therapeutic opportunities in the treatment of SWI/SNF-defective cancers. Seminars in Cancer Biology, 2020, 61, 180-198.	4.3	28
161	Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review. Expert Review of Molecular Diagnostics, 2020, 20, 169-185.	1.5	21
162	Immune checkpoint inhibition for the treatment of renal cell carcinoma. Expert Opinion on Biological Therapy, 2020, 20, 83-94.	1.4	14
163	Unraveling LGALS1 as a Potential Immune Checkpoint and a Predictor of the Response to Anti-PD1 Therapy in Clear Cell Renal Carcinoma. Pathology and Oncology Research, 2020, 26, 1451-1458.	0.9	17
164	An Update on Predictive Biomarkers in Metastatic Renal Cell Carcinoma. European Urology Focus, 2020, 6, 34-36.	1.6	25
165	Expression of PBRM1 as a prognostic predictor in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitor. International Journal of Clinical Oncology, 2020, 25, 338-346.	1.0	3
166	Machine learning-based unenhanced CT texture analysis for predicting BAP1 mutation status of clear cell renal cell carcinomas. Acta Radiologica, 2020, 61, 856-864.	0.5	30

#	Article	IF	Citations
167	SWI/SNF complex heterogeneity is related to polyphenotypic differentiation, prognosis, and immune response in rhabdoid tumors. Neuro-Oncology, 2020, 22, 785-796.	0.6	18
168	Understanding genetic determinants of resistance to immune checkpoint blockers. Seminars in Cancer Biology, 2020, 65, 123-139.	4.3	9
169	Modulation of SRSF2 expression reverses the exhaustion of TILs via the epigenetic regulation of immune checkpoint molecules. Cellular and Molecular Life Sciences, 2020, 77, 3441-3452.	2.4	22
170	Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, e350-e359.	0.9	3
171	Biomarkers for Response to Immune Checkpoint Blockade. Annual Review of Cancer Biology, 2020, 4, 331-351.	2.3	29
172	Prognostic value of infiltrating immune cells in clear cell renal cell carcinoma (ccRCC). Journal of Cellular Biochemistry, 2020, 121, 2571-2581.	1.2	21
173	Brain immunology and immunotherapy in brain tumours. Nature Reviews Cancer, 2020, 20, 12-25.	12.8	389
174	Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma. Cancers, 2020, 12, 16.	1.7	72
175	Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer. , 2020, 8, e001126.		54
176	Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors. AAPS Journal, 2020, 22, 132.	2.2	27
177	Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies. Trends in Genetics, 2020, 36, 936-950.	2.9	172
178	Prognostic and Predictive Factors in Metastatic Renal Cell Carcinoma. Cancer Journal (Sudbury, Mass) Tj ETQq1 1 0.784314 rgBT /Overl	1.0	6
179	Prognostic Value of YTHDF2 in Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2020, 10, 1566.	1.3	6
180	BIRC2 Expression Impairs Anti-Cancer Immunity and Immunotherapy Efficacy. Cell Reports, 2020, 32, 108073.	2.9	30
181	Transcriptomic characterization and innovative molecular classification of clear cell renal cell carcinoma in the Chinese population. Cancer Cell International, 2020, 20, 461.	1.8	10
182	Cytoreductive Nephrectomy in Patients Presenting With Advanced Disease. Cancer Journal (Sudbury,) Tj ETQq1 1 0.784314 rgBT /Overl	1.0	F
183	Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. Biomedicine and Pharmacotherapy, 2020, 130, 110621.	2.5	8
184	Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology. Human Molecular Genetics, 2020, 29, R214-R225.	1.4	3

#	Article	IF	Citations
185	The Resistance Mechanisms of Lung Cancer Immunotherapy. Frontiers in Oncology, 2020, 10, 568059.	1.3	47
186	Molecular alterations in meningioma: prognostic and therapeutic perspectives. Current Opinion in Oncology, 2020, 32, 613-622.	1.1	51
187	Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis. , 2020, 8, e000953.		32
188	Pbrm1 Steers Mesenchymal Stromal Cell Osteolineage Differentiation by Integrating PBAF-Dependent Chromatin Remodeling and BMP/TGF-Î² Signaling. Cell Reports, 2020, 31, 107570.	2.9	24
189	Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. Drug Resistance Updates, 2020, 53, 100718.	6.5	103
190	The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer. PLoS ONE, 2020, 15, e0235705.	1.1	44
191	Targeting the Deterministic Evolutionary Trajectories of Clear Cell Renal Cell Carcinoma. Cancers, 2020, 12, 3300.	1.7	6
192	Biomarker Development for Metastatic Renal Cell Carcinoma: Omics, Antigens, T-cells, and Beyond. Journal of Personalized Medicine, 2020, 10, 225.	1.1	7
193	Pan-cancer analysis of NLRP3 inflammasome with potential implications in prognosis and immunotherapy in human cancer. Briefings in Bioinformatics, 2021, 22, .	3.2	73
194	<p>Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma</p>. ImmunoTargets and Therapy, 2020, Volume 9, 273-288.	2.7	9
195	Establishment and Validation of a Prognostic Risk Model for Autophagy-Related Genes in Clear Cell Renal Cell Carcinoma. Disease Markers, 2020, 2020, 1-11.	0.6	4
196	Integrated molecular drivers coordinate biological and clinical states in melanoma. Nature Genetics, 2020, 52, 1373-1383.	9.4	36
197	PBRM1 and the glycosylphosphatidylinositol biosynthetic pathway promote tumor killing mediated by MHC-unrestricted cytotoxic lymphocytes. Science Advances, 2020, 6, .	4.7	8
198	The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?. Molecular Cancer, 2020, 19, 170.	7.9	32
199	Patient Stratification of Clear Cell Renal Cell Carcinoma Using the Global Transcription Factor Activity Landscape Derived From RNA-Seq Data. Frontiers in Oncology, 2020, 10, 526577.	1.3	7
200	Genetic Alterations in Renal Cancers: Identification of The Mechanisms Underlying Cancer Initiation and Progression and of Therapeutic Targets. Medicines (Basel, Switzerland), 2020, 7, 44.	0.7	13
201	Inactivating mutations in genes encoding for components of the BAF/PBAF complex and immune-checkpoint inhibitor outcome. Biomarker Research, 2020, 8, 26.	2.8	3
202	Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatmentâ€"Current Progress, Strategy, and Future Perspective. Frontiers in Immunology, 2020, 11, 1508.	2.2	60

#	ARTICLE	IF	CITATIONS
203	Unraveling the Complexity of the Cancer Microenvironment With Multidimensional Genomic and Cytometric Technologies. Frontiers in Oncology, 2020, 10, 1254.	1.3	45
204	Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing. Scientific Reports, 2020, 10, 12581.	1.6	83
205	High-dimensional Cytometry (ExCYT) and Mass Spectrometry of Myeloid Infiltrate in Clinically Localized Clear Cell Renal Cell Carcinoma Identifies Novel Potential Myeloid Targets for Immunotherapy. Molecular and Cellular Proteomics, 2020, 19, 1850-1859.	2.5	2
206	The Genomic Landscape of <i>SMARCA4</i> Alterations and Associations with Outcomes in Patients with Lung Cancer. Clinical Cancer Research, 2020, 26, 5701-5708.	3.2	133
207	The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials. Cancers, 2020, 12, 1945.	1.7	49
208	The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy. Immunotherapy, 2020, 12, 1083-1100.	1.0	27
209	Mechanisms of Cancer Resistance to Immunotherapy. Frontiers in Oncology, 2020, 10, 1290.	1.3	159
210	Germline genomes have a dominant€heritable contribution to cancer immune evasion and immunotherapy response. Quantitative Biology, 2020, 8, 216-227.	0.3	2
211	Clonal tracing reveals diverse patterns of response to immune checkpoint blockade. Genome Biology, 2020, 21, 263.	3.8	15
212	<p>miR-758-3p Inhibits Proliferation, Migration, and Invasion of Clear Cell Renal Cell Carcinoma and Predicts Favorable Prognosis</p>. Cancer Management and Research, 2020, Volume 12, 9285-9295.	0.9	4
213	Genomic Analysis Reveals Novel Specific Metastatic Mutations in Chinese Clear Cell Renal Cell Carcinoma. BioMed Research International, 2020, 2020, 1-9.	0.9	9
214	Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types. Genome Medicine, 2020, 12, 90.	3.6	29
215	<p>High Expression of CD39 is Associated with Poor Prognosis and Immune Infiltrates in Clear Cell Renal Cell Carcinoma</p>. OncoTargets and Therapy, 2020, Volume 13, 10453-10464.	1.0	11
216	BAP1: Not just a BRCA1-associated protein. Cancer Treatment Reviews, 2020, 90, 102091.	3.4	89
217	Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomarker Research, 2020, 8, 34.	2.8	266
218	Cancer-Specific Immune Prognostic Signature in Solid Tumors and Its Relation to Immune Checkpoint Therapies. Cancers, 2020, 12, 2476.	1.7	39
219	Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma. Cancers, 2020, 12, 2662.	1.7	31
220	ARID2 Chromatin Remodeler in Hepatocellular Carcinoma. Cells, 2020, 9, 2152.	1.8	12

#	ARTICLE	IF	CITATIONS
221	Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer. Seminars in Cancer Biology, 2021, 77, 127-143.	4.3	59
222	Integrated Genomic Characterization of the Human Immunome in Cancer. Cancer Research, 2020, 80, 4854-4867.	0.4	11
223	An algorithm to quantify intratumor heterogeneity based on alterations of gene expression profiles. Communications Biology, 2020, 3, 505.	2.0	50
224	Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer. Frontiers in Oncology, 2020, 10, 1644.	1.3	48
225	A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response. Nature Communications, 2020, 11, 4168.	5.8	46
226	Tissue Based Biomarkers for Metastatic Clear Cell Renal Carcinoma: A Systematic Review. Kidney Cancer, 2020, 4, 197-210.	0.2	1
227	Alpha Thalassemia/Intellectual Disability X-Linked Deficiency Sensitizes Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors. Frontiers in Oncology, 2020, 10, 608300.	1.3	6
228	<p>Review of Adjuvant Therapies in Renal Cell Carcinoma: Evidence to Date</p>. OncoTargets and Therapy, 2020, Volume 13, 12301-12316.	1.0	22
229	Biomarkers Towards New Era of Therapeutics for Metastatic Renal Cell Carcinoma. Kidney Cancer, 2020, 4, 61-69.	0.2	1
230	PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nature Communications, 2020, 11, 2135.	5.8	114
231	The Impact of Age and Gender on Outcomes of Patients With Advanced Renal Cell Carcinoma Treated With Targeted Therapy. Clinical Genitourinary Cancer, 2020, 18, e598-e609.	0.9	11
232	MHC-I genotype and tumor mutational burden predict response to immunotherapy. Genome Medicine, 2020, 12, 45.	3.6	70
233	Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC. Biomedicine and Pharmacotherapy, 2020, 127, 109996.	2.5	35
234	Renal Cell and Urothelial Carcinoma: Biomarkers for New Treatments. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e197-e206.	1.8	10
235	High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas. Diagnostic Pathology, 2020, 15, 50.	0.9	34
236	Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features. Acta Neuropathologica, 2020, 140, 89-93.	3.9	32
237	Bayesian multiple instance regression for modeling immunogenic neoantigens. Statistical Methods in Medical Research, 2020, 29, 3032-3047.	0.7	8
238	HIF1A expression correlates with increased tumor immune and stromal signatures and aggressive phenotypes in human cancers. Cellular Oncology (Dordrecht), 2020, 43, 877-888.	2.1	25

#	ARTICLE	IF	CITATIONS
239	In situ conversion of defective Treg into SuperTreg cells to treat advanced IPEX-like disorders in mice. Nature Communications, 2020, 11, 2781.	5.8	7
240	CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma. , 2020, 8, e000228.		15
241	CRISPR screen in mechanism and target discovery for cancer immunotherapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188378.	3.3	25
242	Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e275-e291.	1.8	32
243	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nature Medicine, 2020, 26, 909-918.	15.2	488
244	Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade. Cancer Discovery, 2020, 10, 1140-1157.	7.7	97
245	The Pan-Omics Landscape of Renal Cell Carcinoma and Its Implication on Future Clinical Practice. Kidney Cancer, 2020, 4, 121-129.	0.2	2
246	Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis. Lung Cancer, 2020, 146, 318-326.	0.9	9
247	Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma. Urologic Clinics of North America, 2020, 47, 293-303.	0.8	25
248	Construction of a 13-Gene Signature as a Novel Prognostic Marker for Patients with Clear Cell Renal Cell Carcinoma and the Role of XCR1 in Cell Proliferation . Cancer Management and Research, 2020, Volume 12, 4017-4027.	0.9	2
249	Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer. Targeted Oncology, 2020, 15, 377-390.	1.7	15
250	Sequencing Therapies for Metastatic Renal Cell Carcinoma. Urologic Clinics of North America, 2020, 47, 305-318.	0.8	14
251	Genomic profiling in renal cell carcinoma. Nature Reviews Nephrology, 2020, 16, 435-451.	4.1	99
252	A 17-Gene Signature Predicted Prognosis in Renal Cell Carcinoma. Disease Markers, 2020, 2020, 1-9.	0.6	6
253	The roles of mutated SWI/SNF complexes in the initiation and development of hepatocellular carcinoma and its regulatory effect on the immune system: A review. Cell Proliferation, 2020, 53, e12791.	2.4	23
254	PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer. Npj Precision Oncology, 2020, 4, 6.	2.3	32
255	Tumor Microenvironment. Cancer Treatment and Research, 2020, , .	0.2	12
256	<i>ARID1A</i>alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy. , 2020, 8, e000438.		117

#	ARTICLE	IF	CITATIONS
257	Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group. Annals of Oncology, 2020, 31, 978-990.	0.6	87
259	Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective. International Journal of Molecular Sciences, 2020, 21, 4691.	1.8	40
260	Role of DNA repair defects in predicting immunotherapy response. Biomarker Research, 2020, 8, 23.	2.8	47
261	Construction of an integrated prognostic classifier model for predicting the efficacy of immune checkpoint inhibitor therapy in non‐small cell lung cancer. Cancer Communications, 2020, 40, 370-373.	3.7	6
262	Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer. Cells, 2020, 9, 1495.	1.8	8
263	TUBB3 Is Associated with High-Grade Histology, Poor Prognosis, p53 Expression, and Cancer Stem Cell Markers in Clear Cell Renal Cell Carcinoma. Oncology, 2020, 98, 689-698.	0.9	15
264	Molecular characteristics and markers of advanced clear cell renal cell carcinoma: Pitfalls due to intratumoral heterogeneity and identification of genetic alterations associated with metastasis. International Journal of Urology, 2020, 27, 790-797.	0.5	7
265	Cancer Epigenetics, Tumor Immunity, and Immunotherapy. Trends in Cancer, 2020, 6, 580-592.	3.8	166
266	Identification of gene signature for treatment response to guide precision oncology in clear-cell renal cell carcinoma. Scientific Reports, 2020, 10, 2026.	1.6	16
267	Effect of m6A RNA Methylation Regulators on Malignant Progression and Prognosis in Renal Clear Cell Carcinoma. Frontiers in Oncology, 2020, 10, 3.	1.3	61
268	Recent advances in the biology of tumour hypoxia with relevance to diagnostic practice and tissue‐based research. Journal of Pathology, 2020, 250, 593-611.	2.1	23
269	Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. Annals of Oncology, 2020, 31, 599-608.	0.6	183
270	Renal Cell Carcinoma: genomic landscape and clinical implications. Expert Review of Precision Medicine and Drug Development, 2020, 5, 95-100.	0.4	1
271	Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes. Science Immunology, 2020, 5, .	5.6	39
272	Synthetic lethal therapy based on targeting the vulnerability of SWI/SNF chromatin remodeling complex‐deficient cancers. Cancer Science, 2020, 111, 774-782.	1.7	32
273	Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100. Cancer Science, 2020, 111, 1324-1332.	1.7	27
274	Germline Features Associated with Immune Infiltration in Solid Tumors. Cell Reports, 2020, 30, 2900-2908.e4.	2.9	35
275	Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?. Oncologist, 2020, 25, 94-98.	1.9	58

#	Article	IF	Citations
276	Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts. Gynecologic Oncology, 2020, 157, 106-114.	0.6	29
277	Cancer immunotherapy: Pros, cons and beyond. Biomedicine and Pharmacotherapy, 2020, 124, 109821.	2.5	337
278	Tumor Milieu Controlled by RB Tumor Suppressor. International Journal of Molecular Sciences, 2020, 21, 2450.	1.8	17
279	Immunotherapy in Renal Cell Carcinoma: The Future Is Now. International Journal of Molecular Sciences, 2020, 21, 2532.	1.8	126
280	Advances in theranostic biomarkers for tumor immunotherapy. Current Opinion in Chemical Biology, 2020, 56, 79-90.	2.8	27
281	Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer Treatment Reviews, 2020, 86, 102019.	3.4	327
282	*PRKDC*: new biomarker and drug target for checkpoint blockade immunotherapy. , 2020, 8, e000485.		32
283	*LAG3* (*LAG-3*, *CD223*) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma. , 2020, 8, e000552.		70
284	Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response. Clinical Cancer Research, 2020, 26, 3901-3907.	3.2	72
285	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. Cancer Immunology Research, 2020, 8, 1075-1084.	1.6	47
286	The genetic landscapes of urological cancers and their clinical implications in the era of high-throughput genome analysis. BJU International, 2020, 126, 26-54.	1.3	5
287	The SWI/SNF complex in cancer â€" biology, biomarkers and therapy. Nature Reviews Clinical Oncology, 2020, 17, 435-448.	12.5	297
288	Small-Cell Carcinoma of the Ovary, Hypercalcemic Typeâ€"Genetics, New Treatment Targets, and Current Management Guidelines. Clinical Cancer Research, 2020, 26, 3908-3917.	3.2	82
289	An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer. Molecular Cancer Therapeutics, 2020, 19, 1373-1382.	1.9	20
290	Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression. Clinical Cancer Research, 2020, 26, 3629-3640.	3.2	30
291	Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival. Genome Medicine, 2020, 12, 33.	3.6	67
292	Coalescing lessons from oxygen sensing, tumor metabolism, and epigenetics to target VHL loss in kidney cancer. Seminars in Cancer Biology, 2020, 67, 34-42.	4.3	12
293	Computational recognition of lncRNA signature of tumor-infiltrating B lymphocytes with potential implications in prognosis and immunotherapy of bladder cancer. Briefings in Bioinformatics, 2021, 22, .	3.2	126

#	Article	IF	Citations
296	Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma. Cancer Medicine, 2021, 10, 79-86.	1.3	36
297	The Human Protein Atlasâ€"Spatial localization of the human proteome in health and disease. Protein Science, 2021, 30, 218-233.	3.1	102
298	Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nature Reviews Nephrology, 2021, 17, 245-261.	4.1	278
299	Multiomics data reveals the influences of myasthenia gravis on thymoma and its precision treatment. Journal of Cellular Physiology, 2021, 236, 1214-1227.	2.0	6
300	The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy. Journal of Cellular Physiology, 2021, 236, 1616-1627.	2.0	85
301	From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm. Trends in Cancer, 2021, 7, 15-28.	3.8	61
302	Immune responses in genomically simple SWI/SNFâ€"deficient cancers. Cancer, 2021, 127, 172-180.	2.0	7
303	Leveraging Automation toward Development of a High-Throughput Gene Expression Profiling Platform. SLAS Discovery, 2021, 26, 410-419.	1.4	3
304	Predicting immunotherapy response through genomics. Current Opinion in Genetics and Development, 2021, 66, 1-9.	1.5	12
305	Dissecting the immunogenomic biology of cancer for biomarker development. Nature Reviews Clinical Oncology, 2021, 18, 133-134.	12.5	7
306	ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma. Journal of Investigative Dermatology, 2021, 141, 1564-1572.e4.	0.3	20
307	Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer. Cancer Medicine, 2021, 10, 53-61.	1.3	39
308	The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell, 2021, 39, 154-173.	7.7	491
309	<scp>SWI</scp>/<scp>SNF</scp>â€‌deficiency defines highly aggressive undifferentiated endometrial carcinoma. Journal of Pathology: Clinical Research, 2021, 7, 144-153.	1.3	38
310	<i>SMARCA4</i> mutations in <i>KRAS</i>â€‌mutant lung adenocarcinoma: a multiâ€‌cohort analysis. Molecular Oncology, 2021, 15, 462-472.	2.1	29
311	The SSPN Score, a Novel Scoring System Incorporating PBRM1 Expression, Predicts Postoperative Recurrence for Patients with Non-metastatic Clear Cell Renal Cell Carcinoma. Annals of Surgical Oncology, 2021, 28, 2359-2366.	0.7	9
312	Clinical Benefit From Immune Checkpoint Blockade in Sclerosing Epithelioid Fibrosarcoma: A Translocation-Associated Sarcoma. JCO Precision Oncology, 2021, 5, 1-5.	1.5	7
313	Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma. Nature Medicine, 2021, 27, 289-300.	15.2	64

#	Article	IF	Citations
314	Genetic analysis of primary renal cell carcinoma to determine treatment approaches. Expert Review of Precision Medicine and Drug Development, 2021, 6, 107-115.	0.4	1
315	Comprehensive Characterization of Tumor Microenvironment Differences in Cancer between Male and Female Patients. SSRN Electronic Journal, 0, , .	0.4	0
316	Response to systemic therapy in locally advanced and metastatic renal cell carcinoma: can it be predicted?. Expert Review of Anticancer Therapy, 2021, 21, 629-639.	1.1	0
317	Clinical challenges in neoadjuvant immunotherapy for non-small cell lung cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2021, 33, 203-215.	0.7	3
318	Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma. Nature Cancer, 2021, 2, 189-200.	5.7	36
319	Aberrant splicing isoforms detected by full-length transcriptome sequencing as transcripts of potential neoantigens in non-small cell lung cancer. Genome Biology, 2021, 22, 9.	3.8	58
320	Characteristics and prognostic value of potential dependency genes in clear cell renal cell carcinoma based on a large-scale CRISPR-Cas9 and RNAi screening database DepMap. International Journal of Medical Sciences, 2021, 18, 2063-2075.	1.1	23
321	LncRNA HIF1A-AS2 accelerates malignant phenotypes of renal carcinoma by modulating miR-30a-5p/SOX4 axis as a ceRNA. Cancer Biology and Medicine, 2021, 18, 587-603.	1.4	15
322	Update on the most promising biomarkers of response to immune checkpoint inhibitors in clear cell renal cell carcinoma. World Journal of Urology, 2021, 39, 1377-1385.	1.2	15
323	LRP2 and DOCK8 are Potential Antigens for mRNA Vaccine Development in Immunologically â€˜Coldâ€™ KIRC Tumours. SSRN Electronic Journal, 0, , .	0.4	0
324	Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer. Theranostics, 2021, 11, 3089-3108.	4.6	207
325	A genomic instability-derived risk index predicts clinical outcome and immunotherapy response for clear cell renal cell carcinoma. Bioengineered, 2021, 12, 1642-1662.	1.4	6
326	Emerging role of SWI/SNF complex deficiency as a target of immune checkpoint blockade in human cancers. Oncogenesis, 2021, 10, 3.	2.1	25
327	Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC). Cancers, 2021, 13, 231.	1.7	42
328	Mapping the immune environment in clear cell renal carcinoma by single-cell genomics. Communications Biology, 2021, 4, 122.	2.0	139
329	OUP accepted manuscript. Japanese Journal of Clinical Oncology, 2021, , .	0.6	11
330	Development of a novel gene signature to predict prognosis and response to PD-1 blockade in clear cell renal cell carcinoma. OncoImmunology, 2021, 10, 1933332.	2.1	26
331	Whole genome sequencing of skull-base chordoma reveals genomic alterations associated with recurrence and chordoma-specific survival. Nature Communications, 2021, 12, 757.	5.8	55

#	Article	IF	Citations
332	Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nature Medicine, 2021, 27, 212-224.	15.2	376
333	Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma. Cancers, 2021, 13, 667.	1.7	27
334	Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer. Molecular Cancer, 2021, 20, 29.	7.9	139
335	Tumor Immune Microenvironment Characterization in Hepatocellular Carcinoma Identifies Four Prognostic and Immunotherapeutically Relevant Subclasses. Frontiers in Oncology, 2020, 10, 610513.	1.3	17
336	Comprehensive analyses of PBRM1 in multiple cancer types and its association with clinical response to immunotherapy and immune infiltrates. Annals of Translational Medicine, 2021, 9, 465-465.	0.7	14
337	Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer. Frontiers in Immunology, 2021, 12, 630773.	2.2	22
338	Subgroup-Independent Mapping of Renal Cell Carcinoma—Machine Learning Reveals Prognostic Mitochondrial Gene Signature Beyond Histopathologic Boundaries. Frontiers in Oncology, 2021, 11, 621278.	1.3	31
339	A BAP1 synonymous mutation results in exon skipping, loss of function and worse patient prognosis. IScience, 2021, 24, 102173.	1.9	13
340	Neo-Fs Index: A Novel Immunohistochemical Biomarker Panel Predicts Survival and Response to Anti-Angiogenetic Agents in Clear Cell Renal Cell Carcinoma. Cancers, 2021, 13, 1199.	1.7	2
341	Finding predictive factors for immunotherapy in metastatic renal-cell carcinoma: What are we looking for?. Cancer Treatment Reviews, 2021, 94, 102157.	3.4	16
342	RNA Modification of N6-Methyladenosine Predicts Immune Phenotypes and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma. Frontiers in Oncology, 2021, 11, 642159.	1.3	30
343	Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma. Cancers, 2021, 13, 1475.	1.7	10
344	Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). Cancer, 2021, 127, 2204-2212.	2.0	32
345	Circulating mucosal-associated invariant T cells identify patients responding to anti-PD-1 therapy. Nature Communications, 2021, 12, 1669.	5.8	48
346	Integrative radiogenomics analysis for predicting molecular features and survival in clear cell renal cell carcinoma. Aging, 2021, 13, 9960-9975.	1.4	19
347	Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC. , 2021, 9, e001506.		23
349	Comprehensive analysis of immune-related prognostic genes in the tumour microenvironment of hepatocellular carcinoma. BMC Cancer, 2021, 21, 331.	1.1	1
350	Individualizing renal cell carcinoma treatment through biomarkers discovery in the era of immune checkpoint inhibitors: where do we stand?. Current Opinion in Urology, 2021, 31, 236-241.	0.9	4

#	ARTICLE	IF	CITATIONS
351	DNA methylation as predictive marker of response to immunotherapy?. Memo - Magazine of European Medical Oncology, 2021, 14, 150-153.	0.3	3
352	Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma. Frontiers in Immunology, 2021, 12, 653358.	2.2	19
353	Renal cell carcinoma pathology in 2021: â€˜new need for renal cancer immune profilingâ€™. Current Opinion in Urology, 2021, 31, 228-235.	0.9	5
354	Renal Cell Carcinoma With Urinary Bladder Metastasis: A Case Report With Metachronous Genomic Analyses. JCO Precision Oncology, 2021, 5, 557-560.	1.5	1
355	The Immune-Related Gene HCST as a Novel Biomarker for the Diagnosis and Prognosis of Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 630706.	1.3	5
357	Transformation of a cold to hot tumor and a durable response to immunotherapy in a patient with non-small cell lung cancer after chemoradiotherapy: a case report. Annals of Palliative Medicine, 2021, 10, 4982-4986.	0.5	3
358	The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic Treatments. Cancers, 2021, 13, 2071.	1.7	25
359	Predictive biomarkers for response to immune checkpoint inhibition. Seminars in Cancer Biology, 2022, 79, 4-17.	4.3	70
360	Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial. PLoS ONE, 2021, 16, e0248097.	1.1	5
361	Synthetic lethality-mediated precision oncology via the tumor transcriptome. Cell, 2021, 184, 2487-2502.e13.	13.5	60
362	Therapeutic cancer vaccines. Nature Reviews Cancer, 2021, 21, 360-378.	12.8	630
363	Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy. Cancers, 2021, 13, 1639.	1.7	13
364	Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker. Journal of the National Cancer Institute, 2021, 113, 1634-1647.	3.0	28
365	A pan-cancer analysis of CpG Island gene regulation reveals extensive plasticity within Polycomb target genes. Nature Communications, 2021, 12, 2485.	5.8	21
366	Addressing resistance to immune checkpoint inhibitor therapy:Âan urgent unmet need. Future Oncology, 2021, 17, 1401-1439.	1.1	17
368	Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell, 2021, 39, 649-661.e5.	7.7	263
369	Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity. Nature, 2021, 595, 309-314.	13.7	181
370	A pan-cancer transcriptome analysis of exitron splicing identifies novel cancer driver genes and neoepitopes. Molecular Cell, 2021, 81, 2246-2260.e12.	4.5	35

#	Article	IF	Citations
371	Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma. European Urology Focus, 2022, 8, 784-793.	1.6	12
372	METTL13 inhibits progression of clear cell renal cell carcinoma with repression on PI3K/AKT/mTOR/HIF-1Î± pathway and c-Myc expression. Journal of Translational Medicine, 2021, 19, 209.	1.8	14
373	High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab. Molecular Cancer Research, 2021, 19, 1510-1521.	1.5	20
374	Translational Applications of Hydrogels. Chemical Reviews, 2021, 121, 11385-11457.	23.0	438
375	Clinical Perspectives to Overcome Acquired Resistance to Antiâ€"Programmed Death-1 and Antiâ€"Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer. Molecules and Cells, 2021, 44, 363-373.	1.0	13
376	PD-L1 Regulates Inflammation in LPS-Induced Lung Epithelial Cells and Vascular Endothelial Cells by Interacting with the HIF-1Î± Signaling Pathway. Inflammation, 2021, 44, 1969-1981.	1.7	14
377	Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer. International Journal of Molecular Sciences, 2021, 22, 5158.	1.8	3
378	PD-1 Coexpression Gene Analysis and the Regulatory Network in Endometrial Cancer Based on Bioinformatics Analysis. BioMed Research International, 2021, 2021, 1-7.	0.9	1
379	Single-cell sequencing links multiregional immune landscapes and tissue-resident TÂcells in ccRCC to tumor topology and therapy efficacy. Cancer Cell, 2021, 39, 662-677.e6.	7.7	179
380	Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell, 2021, 39, 632-648.e8.	7.7	230
381	MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells. Oncogene, 2021, 40, 4930-4940.	2.6	41
383	PBRM1 Mutations as a Predictive Biomarker for Immunotherapy in Metastatic Renal Cell Carcinoma: A Systematic Review. Kidney Cancer, 2021, 5, 79-92.	0.2	2
384	A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 10.e1-10.e6.	0.8	20
385	Bioinformatics analysis and verification of gene targets for renal clear cell carcinoma. Computational Biology and Chemistry, 2021, 92, 107453.	1.1	15
387	Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 4807-4813.	3.2	9
388	PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer. Cancer Research, 2021, 81, 2888-2902.	0.4	66
389	Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell, 2021, 39, 845-865.e7.	7.7	503
390	Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy. Npj Precision Oncology, 2021, 5, 51.	2.3	46

#	Article	IF	Citations
391	Pan-cancer characterization of lncRNA modifiers of immune microenvironment reveals clinically distinct de novo tumor subtypes. Npj Genomic Medicine, 2021, 6, 52.	1.7	15
393	A Novel Ferroptosis-Related Pathway for Regulating Immune Checkpoints in Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 678694.	1.3	6
394	Upregulation of ARNTL2 is associated with poor survival and immune infiltration in clear cell renal cell carcinoma. Cancer Cell International, 2021, 21, 341.	1.8	11
395	Role of Oncogenic Pathways on the Cancer Immunosuppressive Microenvironment and Its Clinical Implications in Hepatocellular Carcinoma. Cancers, 2021, 13, 3666.	1.7	25
397	Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 5595-5606.	3.2	12
398	Molecular Determinants of Soft Tissue Sarcoma Immunity: Targets for Immune Intervention. International Journal of Molecular Sciences, 2021, 22, 7518.	1.8	17
399	Von Hippel-Lindau tumor suppressor pathways & corresponding therapeutics in kidney cancer. Journal of Genetics and Genomics, 2021, 48, 552-559.	1.7	8
400	Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Oncologist, 2021, 26, e1742-e1750.	1.9	17
401	Durable response to immunotherapy plus chemotherapy in a patient with untreated, brain-metastatic, EGFR exon 20 insertion mutation lung adenocarcinoma. Medicine (United States), 2021, 100, e26650.	0.4	5
402	Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach. International Journal of Molecular Sciences, 2021, 22, 8035.	1.8	30
403	Integration of <scp>NRP1</scp>, <scp>RGS5,</scp> and <scp>FOXM1</scp> expression, and tumour necrosis, as a postoperative prognostic classifier based on molecular subtypes of clear cell renal cell carcinoma. Journal of Pathology: Clinical Research, 2021, 7, 590-603.	1.3	6
404	Transcriptomic signatures of tumors undergoing T cell attack. Cancer Immunology, Immunotherapy, 2021, , 1.	2.0	6
405	SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition. Journal of Thoracic Oncology, 2021, 16, 1176-1187.	0.5	49
407	Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis. Nature Communications, 2021, 12, 4172.	5.8	16
408	Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors. Critical Reviews in Oncology/Hematology, 2021, 163, 103390.	2.0	10
409	Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health. Oncologist, 2021, 26, e1786-e1799.	1.9	52
410	The BAF chromatin remodeling complexes: structure, function, and synthetic lethalities. Biochemical Society Transactions, 2021, 49, 1489-1503.	1.6	13
411	Stem Cell Theory of Cancer: Origin of Tumor Heterogeneity and Plasticity. Cancers, 2021, 13, 4006.	1.7	18

#	ARTICLE	IF	CITATIONS
412	CD86 Molecule Might Be a Novel Immune-Related Prognostic Biomarker for Patients With Bladder Cancer by Bioinformatics and Experimental Assays. Frontiers in Oncology, 2021, 11, 679851.	1.3	4
413	Integrated Analysis Of Immunotherapy Treated Clear Cell Renal Cell Carcinomas: An Exploratory Study. Journal of Immunotherapy, 2022, 45, 35-42.	1.2	3
414	Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors. Oncologist, 2021, 26, 1017-1025.	1.9	18
415	Targeting the DNA damage response in immuno-oncology: developments and opportunities. Nature Reviews Cancer, 2021, 21, 701-717.	12.8	150
416	DDX39B Predicts Poor Survival and Associated with Clinical Benefit of Anti-PD-L1 Therapy in ccRCC. Current Cancer Drug Targets, 2021, 21, 849-859.	0.8	4
417	Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. Npj Breast Cancer, 2021, 7, 110.	2.3	20
418	TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. Cancer Immunology Research, 2021, 9, 1202-1213.	1.6	71
419	Is there a role for immune checkpoint inhibitors in chordoma?. Immunotherapy, 2021, 13, 967-970.	1.0	1
420	Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade. Clinical Cancer Research, 2021, 27, 6749-6760.	3.2	39
421	PDâ€1/PDâ€L1 inhibitorsâ€based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies. Cancer Medicine, 2021, 10, 6384-6401.	1.3	10
422	A Somatic Mutation-Derived LncRNA Signature of Genomic Instability Predicts Prognosis for Patients With Liver Cancer. Frontiers in Surgery, 2021, 8, 724792.	0.6	1
423	Prognostic Value of an m5C RNA Methylation Regulator-Related Signature for Clear Cell Renal Cell Carcinoma. Cancer Management and Research, 2021, Volume 13, 6673-6687.	0.9	12
424	Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study. Cancer Medicine, 2021, 10, 6705-6713.	1.3	13
425	Nanotechnology-based immunotherapies to combat cancer metastasis. Molecular Biology Reports, 2021, 48, 6563-6580.	1.0	8
426	Immune Checkpoint Inhibitor in First-Line Treatment of Metastatic Renal Cell Carcinoma: A Review of Current Evidence and Future Directions. Frontiers in Oncology, 2021, 11, 707214.	1.3	26
427	Current status and future perspectives of immunotherapy against urothelial and kidney cancer. Japanese Journal of Clinical Oncology, 2021, 51, 1481-1492.	0.6	7
428	Linking Immunity with Genomics in Sarcomas: Is Genomic Complexity an Immunogenic Trigger?. Biomedicines, 2021, 9, 1048.	1.4	6
429	A 25-year perspective on evaluation and understanding of biomarkers in urologic cancers. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 602-617.	0.8	3

#	Article	IF	Citations
430	Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy. Nature Communications, 2021, 12, 5547.	5.8	31
431	Stem‐cell based, machine learning approach for optimizing natural killer cell‐based personalized immunotherapy for high‐grade ovarian cancer. FEBS Journal, 2022, 289, 985-998.	2.2	3
432	Altered regulation of DPF3, a member of the SWI/SNF complexes, underlies the 14q24 renal cancer susceptibility locus. American Journal of Human Genetics, 2021, 108, 1590-1610.	2.6	9
433	Comprehensive Genomic Landscape in Chinese Clear Cell Renal Cell Carcinoma Patients. Frontiers in Oncology, 2021, 11, 697219.	1.3	5
434	SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer. JCI Insight, 2021, 6, .	2.3	29
435	Recent advances in immunotherapy, immunoadjuvant, and nanomaterial-based combination immunotherapy. Coordination Chemistry Reviews, 2021, 442, 214009.	9.5	29
436	Undifferentiated and dedifferentiated urological carcinomas: lessons learned from the recent developments. Seminars in Diagnostic Pathology, 2021, 38, 152-162.	1.0	3
437	Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade. , 2021, 9, e002922.		19
438	Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer. Life, 2021, 11, 1029.	1.1	8
439	Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. Nature Communications, 2021, 12, 5563.	5.8	19
440	Development and validation of a <i>PBRM1</i>‐associated immune prognostic model for clear cell renal cell carcinoma. Cancer Medicine, 2021, 10, 6590-6609.	1.3	6
441	Mapping genomic and epigenomic evolution in cancer ecosystems. Science, 2021, 373, 1474-1479.	6.0	38
442	Deep learning-based prediction of the T cell receptor–antigen binding specificity. Nature Machine Intelligence, 2021, 3, 864-875.	8.3	99
443	The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation. Science, 2021, 373, 1327-1335.	6.0	83
444	Comprehensive Analysis of m5C RNA Methylation Regulator Genes in Clear Cell Renal Cell Carcinoma. International Journal of Genomics, 2021, 2021, 1-24.	0.8	14
445	Identification of a Novel Epigenetic Signature CHFR as a Potential Prognostic Gene Involved in Metastatic Clear Cell Renal Cell Carcinoma. Frontiers in Genetics, 2021, 12, 720979.	1.1	1
446	Genomic instability in lower-grade glioma: Prediction of prognosis based on lncRNA and immune infiltration. Molecular Therapy - Oncolytics, 2021, 22, 431-443.	2.0	6
447	Refining patient selection for breast cancer immunotherapy: beyond PD-L1. ESMO Open, 2021, 6, 100257.	2.0	13

#	Article	IF	Citations
448	Pan-cancer analysis reveals that neurotrophin signaling correlates positively with anti-tumor immunity, clinical outcomes, and response to targeted therapies and immunotherapies in cancer. Life Sciences, 2021, 282, 119848.	2.0	8
449	Cancer cell immune mimicry delineates onco-immunologic modulation. IScience, 2021, 24, 103133.	1.9	9
450	A case of radio-insensitive SMARCA4-deficient thoracic undifferentiated carcinoma with severe right heart failure. Respiratory Medicine Case Reports, 2021, 32, 101364.	0.2	1
451	Typical Tumor Immune Microenvironment Status Determine Prognosis in Lung Adenocarcinoma. SSRN Electronic Journal, 0, , .	0.4	0
452	Development and Clinical Validation of a Seven-Gene Prognostic Signature Based on Multiple Machine Learning Algorithms in Kidney Cancer. Cell Transplantation, 2021, 30, 096368972096917.	1.2	9
453	The Era of Radiogenomics in Precision Medicine: An Emerging Approach to Support Diagnosis, Treatment Decisions, and Prognostication in Oncology. Frontiers in Oncology, 2020, 10, 570465.	1.3	60
454	Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma. Nature Reviews Clinical Oncology, 2021, 18, 199-214.	12.5	179
455	Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors. Cancer Treatment and Research, 2020, 180, 251-279.	0.2	15
456	Rational Discovery of Response Biomarkers: Candidate Prognostic Factors and Biomarkers for Checkpoint Inhibitor-Based Immunotherapy. Advances in Experimental Medicine and Biology, 2020, 1248, 143-166.	0.8	3
457	Checkpoint inhibitor immunotherapy in kidney cancer. Nature Reviews Urology, 2020, 17, 137-150.	1.9	162
470	Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma. , 2020, 8, e000319.		67
471	Endogenous retrovirus expression is associated with response to immune checkpoint pathway in clear cell renal cell carcinoma. JCI Insight, 2018, 3, .	2.3	128
472	Failed immune responses across multiple pathologies share pan-tumor and circulating lymphocytic targets. Journal of Clinical Investigation, 2019, 129, 2463-2479.	3.9	4
473	IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. Journal of Clinical Investigation, 2019, 129, 3324-3338.	3.9	209
474	Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. Journal of Clinical Investigation, 2020, 130, 2712-2726.	3.9	112
475	Low intratumor heterogeneity correlates with increased response to PD-1 blockade in renal cell carcinoma. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097711.	1.4	20
476	EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers. BMC Medicine, 2021, 19, 26.	2.3	27
477	Exploiting the circuit breaker cancer evolution model in human clear cell renal cell carcinoma. Cell Stress, 2020, 4, 191-198.	1.4	3

#	ARTICLE	IF	CITATIONS
478	Overexpression of steroid sulfotransferase genes is associated with worsened prognosis and with immune exclusion in clear cell-renal cell carcinoma. Aging, 2019, 11, 9209-9219.	1.4	2
479	Development and validation of a metastasis-associated prognostic signature based on single-cell RNA-seq in clear cell renal cell carcinoma. Aging, 2019, 11, 10183-10202.	1.4	28
480	TP53 somatic mutations are associated with poor survival in non-small cell lung cancer patients who undergo immunotherapy. Aging, 2020, 12, 14556-14568.	1.4	20
481	Identification of immune-related LncRNA for predicting prognosis and immunotherapeutic response in bladder cancer. Aging, 2020, 12, 23306-23325.	1.4	59
482	Development and validation of a prognostic model for kidney renal clear cell carcinoma based on RNA binding protein expression. Aging, 2020, 12, 25356-25372.	1.4	13
483	Identification of prognostic chromatin-remodeling genes in clear cell renal cell carcinoma. Aging, 2020, 12, 25614-25642.	1.4	4
484	The landscape of novel and complementary targets for immunotherapy: an analysis of gene expression in the tumor microenvironment. Oncotarget, 2019, 10, 4532-4545.	0.8	8
485	https://cdrjournal.com/article/view/3531. , 2020, 3, 454-471.		4
486	Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targetsâ€"a narrative review. Annals of Translational Medicine, 2020, 8, 1712-1712.	0.7	36
487	Clinicopathological and prognostic impact of somatic mutations in Chinese patients with clear cell renal cell carcinoma. Translational Andrology and Urology, 2020, 9, 2751-2763.	0.6	7
488	Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade. Frontiers in Immunology, 2020, 11, 339.	2.2	77
489	Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer. ELife, 2018, 7, .	2.8	25
491	Significance of CD8+ T cell infiltration-related biomarkers and the corresponding prediction model for the prognosis of kidney renal clear cell carcinoma. Aging, 2021, 13, 22912-22933.	1.4	3
492	Risk prediction for metastasis of clear cell renal cell carcinoma using digital multiplex ligationâ€dependent probe amplification. Cancer Science, 2022, 113, 297-307.	1.7	4
493	PBRM1 Regulates the Stress Response in Epithelial Cells. SSRN Electronic Journal, 0, , .	0.4	0
494	Quelle stratÃ©gie thÃ©rapeutique pour les stades mÃ©tastatiques ?. Oncologie, 2018, 20, 211-219.	0.2	0
496	Genomic Applications and Insights in Unravelling Cancer Signalling Pathways. , 2019, , 471-511.		0
497	Neoantigen Clonal Balance Predicts Immunotherapy Outcomes and Prognosis. SSRN Electronic Journal, 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
499	Evolving Role of Genomics in Genitourinary Neoplasms. Acta Medica Academica, 2019, 48, 68.	0.3	2
501	Biomarkers in metastatic renal cell carcinoma in the era of immune checkpoint inhibitors. Annals of Translational Medicine, 2019, 7, S203-S203.	0.7	1
504	Predicting the polybromo-1 (PBRM1) mutation of a clear cell renal cell carcinoma using computed tomography images and KNN classification with random subspace. Vibroengineering PROCEDIA, 2019, 26, 30-34.	0.3	3
505	Defining an Individualized Treatment Strategy for Metastatic Renal Cancer. , 2020, , 437-452.		0
507	Latest progress in molecular biology and treatment in genitourinary tumours. Clinical and Translational Oncology, 2020, 22, 2175-2195.	1.2	2
511	Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell, 2021, 39, 1497-1518.e11.	7.7	126
512	Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers. Science Translational Medicine, 2021, 13, eabe6201.	5.8	19
513	Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers. Cancers, 2021, 13, 5415.	1.7	13
514	Programmed Cell Death Protein Ligand 2 Is a Potential Biomarker That Predicts the Efficacy of Immunotherapy. Disease Markers, 2021, 2021, 1-10.	0.6	2
515	ParsVNN: parsimony visible neural networks for uncovering cancer-specific and drug-sensitive genes and pathways. NAR Genomics and Bioinformatics, 2021, 3, lqab097.	1.5	12
519	Renal Cancer Including Molecular Characterization. , 2020, , 551-559.		0
520	*In vivo* CRISPR Screens Identify E3 Ligase *Cop1* as a Modulator of Macrophage Infiltration and Cancer Immunotherapy Target. SSRN Electronic Journal, 0, , .	0.4	0
522	Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03. Clinical Cancer Research, 2022, 28, 489-497.	3.2	36
523	Combination Strategies for Immune Checkpoint Inhibitors in PBRM1-mutant Renal Cell Carcinoma: To PARP or Not To PARP?. European Urology, 2022, 81, 149-150.	0.9	3
524	CCL5-dependent mast cell infiltration into the tumor microenvironment in clear cell renal cell carcinoma patients. Aging, 2020, 12, 21809-21836.	1.4	12
525	Adrenal Metastases as Sanctuary Sites in Advanced Renal Cancer. Journal of Kidney Cancer and VHL, 2020, 7, 1-7.	0.2	1
526	Potential roles of PBRM1 on immune infiltration in cholangiocarcinoma. International Journal of Clinical and Experimental Pathology, 2020, 13, 2661-2676.	0.5	1
527	Background, applications and challenges of radiogenomics in genitourinary tumor. American Journal of Cancer Research, 2021, 11, 1936-1945.	1.4	0

#	Article	IF	Citations
528	Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma. Cancers, 2021, 13, 5856.	1.7	39
529	â€œImmune-Cell Pawnsâ€•Plot Promotion and Corner Kidney Cancer: CheckMate 214. European Urology, 2022, 81, 272-273.	0.9	0
530	Immuno-transcriptomic profiling of extracranial pediatric solid malignancies. Cell Reports, 2021, 37, 110047.	2.9	26
531	Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab. Journal of Clinical Medicine, 2021, 10, 5325.	1.0	25
532	From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma. Cells, 2021, 10, 3231.	1.8	18
533	Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma. Cancers, 2021, 13, 5981.	1.7	31
534	Tumor evolution selectively inactivates the core microRNA machinery for immune evasion. Nature Communications, 2021, 12, 7003.	5.8	7
535	HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. Lancet Oncology, The, 2022, 23, 172-184.	5.1	58
536	The renal clear cell carcinoma immune landscape. Neoplasia, 2022, 24, 145-154.	2.3	4
537	Adrenal Metastases as Sanctuary Sites in Advanced Renal Cancer. Journal of Kidney Cancer and VHL, 2020, 7, 1-7.	0.2	4
538	Novel emerging biomarkers to immunotherapy in kidney cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110593.	1.4	12
540	Deep Learningâ€"Based Classification of Epithelialâ€"Mesenchymal Transition for Predicting Response to Therapy in Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 782515.	1.3	3
541	Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?. Cancers, 2022, 14, 644.	1.7	11
542	Prognostic value, DNA variation and immunologic features of a tertiary lymphoid structure-related chemokine signature in clear cell renal cell carcinoma. Cancer Immunology, Immunotherapy, 2022, 71, 1923-1935.	2.0	19
545	The Predictive Value of MAP2K1/2 Mutations on Efficiency of Immunotherapy in Melanoma. Frontiers in Immunology, 2021, 12, 785526.	2.2	6
546	Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. Cancer Cell, 2022, 40, 88-102.e7.	7.7	64
547	mTOR Pathway Gene Mutations Predict Response to Immune Checkpoint Inhibitors in Multiple Cancers. SSRN Electronic Journal, 0, , .	0.4	0
548	T and NK cell abundance defines two distinct subgroups of renal cell carcinoma. OncoImmunology, 2022, 11, 1993042.	2.1	16

#	ARTICLE	IF	CITATIONS
549	miR-181b promotes the oncogenesis of renal cell carcinoma by targeting TIMP3. Biocell, 2022, 46, 1309-1317.	0.4	0
550	Secreted phosphoprotein 1 as a potential prognostic and immunotherapy biomarker in multiple human cancers. Bioengineered, 2022, 13, 3221-3239.	1.4	13
551	Quantification of T- and B-cell Immune Receptor Distribution Diversity Characterizes Immune Cell Infiltration and Lymphocyte Heterogeneity in Clear Cell Renal Cell Carcinoma. Cancer Research, 2022, 82, 929-942.	0.4	13
552	PBRM1 Inactivation Promotes Upregulation of Human Endogenous Retroviruses in a HIF-Dependent Manner. Cancer Immunology Research, 2022, 10, 285-290.	1.6	13
553	Single-Cell RNA Sequencing Reveals the Altered Landscape of Immune Cells in Immune Checkpoint Inhibitor Related Myocarditis. SSRN Electronic Journal, 0, , .	0.4	0
554	Crosstalk Between Four Types of RNA Modification Writers Characterizes the Tumor Immune Microenvironment Infiltration Patterns in Skin Cutaneous Melanoma. Frontiers in Cell and Developmental Biology, 2022, 10, 821678.	1.8	0
555	MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer. OncoImmunology, 2022, 11, 2029298.	2.1	17
556	Transcriptional determinants of cancer immunotherapy response and resistance. Trends in Cancer, 2022, 8, 404-415.	3.8	9
557	Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors. Oncologist, 2022, 27, 501-511.	1.9	14
558	OUP accepted manuscript. Oncologist, 2022, , .	1.9	2
559	Ferroptosis-associated molecular classification characterized by distinct tumor microenvironment profiles in colorectal cancer. International Journal of Biological Sciences, 2022, 18, 1773-1794.	2.6	12
560	Soluble PD-L1 as an early marker of progressive disease on nivolumab. , 2022, 10, e003527.		35
561	Linking a Trio of Molecular Features in Clear-Cell Renal Cell Carcinoma. Cancer Immunology Research, 2022, , .	1.6	1
562	Association of recurrent APOBEC3B alterations with the prognosis of gastric-type cervical adenocarcinoma. Gynecologic Oncology, 2022, 165, 105-113.	0.6	7
563	Clinical response to nivolumab in an INI1-deficient pediatric chordoma correlates with immunogenic recognition of brachyury. Npj Precision Oncology, 2021, 5, 103.	2.3	18
564	Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 793808.	1.3	2
565	Comprehensive assessment of cellular senescence in the tumor microenvironment. Briefings in Bioinformatics, 2022, 23, .	3.2	33
566	PBRM1 Immunohistochemical Expression Profile Correlates with Histomorphological Features and Endothelial Expression of Tumor Vasculature for Clear Cell Renal Cell Carcinoma. Cancers, 2022, 14, 1062.	1.7	3

#	Article	IF	Citations
567	Somatostatin Receptor 2: A Potential Predictive Biomarker for Immune Checkpoint Inhibitor Treatment. Pathology and Oncology Research, 2022, 28, 1610196.	0.9	1
568	Establishing a Prognostic Model Based on Three Genomic Instability-related LncRNAs for Clear Cell Renal Cell Cancer. Clinical Genitourinary Cancer, 2022, , .	0.9	1
569	Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma. Cell Reports Medicine, 2022, 3, 100500.	3.3	13
570	A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape. Genome Medicine, 2022, 14, 20.	3.6	26
571	Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood. Cancer Immunology, Immunotherapy, 2022, 71, 2381-2389.	2.0	2
572	EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1. Nature Communications, 2022, 13, 866.	5.8	51
573	Identification of a Methylation-Regulating Genes Prognostic Signature to Predict the Prognosis and Aid Immunotherapy of Clear Cell Renal Cell Carcinoma. Frontiers in Cell and Developmental Biology, 2022, 10, 832803.	1.8	2
574	Clear cell renal cell carcinoma with stage IV cavoatrial tumour thrombus extension and rapid metastatic reoccurrence postsurgical treatment with review of current treatment strategies. BMJ Case Reports, 2022, 15, e248156.	0.2	1
575	QTL Mapping for Haploid Inducibility Using Genotyping by Sequencing in Maize. Plants, 2022, 11, 878.	1.6	4
576	Integrated Multi-Omics Analysis Identified PTPRG and CHL1 as Key Regulators of Immunophenotypes in Clear Cell Renal Cell Carcinoma(ccRCC). Frontiers in Oncology, 2022, 12, 832027.	1.3	7
577	EGFR Mutation and 11q13 Amplification Are Potential Predictive Biomarkers for Immunotherapy in Head and Neck Squamous Cell Carcinoma. Frontiers in Immunology, 2022, 13, 813732.	2.2	9
578	Pan–cancer analysis reveals sex–specific signatures in the tumor microenvironment. Molecular Oncology, 2022, 16, 2153-2173.	2.1	13
579	Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. , 2022, 10, e004316.		45
580	Sensitivity of *VHL* mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2120403119.	3.3	11
581	Deleterious AHNAK2 Mutation as a Novel Biomarker for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Frontiers in Oncology, 2022, 12, 798401.	1.3	4
582	Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis. , 2022, 10, e004129.		11
583	DEPTH2: an mRNA-based algorithm to evaluate intratumor heterogeneity without reference to normal controls. Journal of Translational Medicine, 2022, 20, 150.	1.8	8
584	Efficacy of second-line ICIs combined with TKIs among patients with metastatic renal cell carcinoma: a real-world study. Immunotherapy, 2022, 14, 309-320.	1.0	0

#	Article	IF	Citations
585	Typical tumor immune microenvironment status determine prognosis in lung adenocarcinoma. Translational Oncology, 2022, 18, 101367.	1.7	10
586	Aneuploidy tolerance caused by BRG1 loss allows chromosome gains and recovery of fitness. Nature Communications, 2022, 13, 1731.	5.8	9
587	Construction and validation of a prognostic model for kidney renal clear cell carcinoma based on podocyte‐associated genes. Cancer Medicine, 2022, , .	1.3	3
588	Intratumor Heterogeneity and Antitumor Immunity Shape One Another Bidirectionally. Clinical Cancer Research, 2022, 28, 2994-3001.	3.2	15
589	Prognostic value and immune infiltration of novel signatures in colon cancer microenvironment. Cancer Cell International, 2021, 21, 679.	1.8	2
590	Conjoint analysis of circulating tumor cells and solid tumors for exploring potential prognostic markers and constructing a robust novel predictive signature for breast cancer. Cancer Cell International, 2021, 21, 708.	1.8	7
591	CD146 as a Prognostic-Related Biomarker in ccRCC Correlating With Immune Infiltrates. Frontiers in Oncology, 2021, 11, 744107.	1.3	11
592	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. Clinical Cancer Research, 2022, 28, 831-839.	3.2	12
593	External Validation of the Prognostic Value of an Immune-Associated Gene Panel for Clear Cell Renal Cell Carcinomas. Frontiers in Cell and Developmental Biology, 2021, 9, 794840.	1.8	2
594	CRISPR Screens to Identify Regulators of Tumor Immunity. Annual Review of Cancer Biology, 2022, 6, 103-122.	2.3	5
595	Integrative 5-Methylcytosine Modification Immunologically Reprograms Tumor Microenvironment Characterizations and Phenotypes of Clear Cell Renal Cell Carcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 772436.	1.8	8
596	Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: aÂmeta-analysis. Immunotherapy, 2022, 14, 617-625.	1.0	3
597	Loss of PBRM1 Alters Promoter Histone Modifications and Activates ALDH1A1 to Drive Renal Cell Carcinoma. Molecular Cancer Research, 2022, 20, 1193-1207.	1.5	7
598	A bipartite graph-based expected networks approach identifies DDR genes not associated with TMB yet predictive of immune checkpoint blockade response. Cell Reports Medicine, 2022, 3, 100602.	3.3	1
610	TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling. Cancer Research, 2022, 82, 2097-2109.	0.4	13
611	Rules of Engagement: The Lymphocyte Receptor Ecosystem in Renal Cell Carcinoma. Cancer Research, 2022, 82, 764-765.	0.4	1
612	Prognostic Impact of Baseline Neutrophil-to-Eosinophil Ratio in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Therapy in Second or Later Lines. Cureus, 2022, 14, e22224.	0.2	2
613	gene expression depends on BAF180 subunit of SWISNF chromatin remodeling complex and correlates with abundance of tumor infiltrating lymphocytes in ccRCC.. American Journal of Cancer Research, 2021, 11, 5965-5978.	1.4	0

#	ARTICLE	IF	CITATIONS
614	Structure of human chromatin-remodelling PBAF complex bound to a nucleosome. Nature, 2022, 605, 166-171.	13.7	42
615	Immune Gene Signature Expression Differs between African American and Caucasian Patients with Renal Cell Carcinoma. Kidney Cancer, 2022, , 1-6.	0.2	0
616	Evidence of Omics, Immune Infiltration, and Pharmacogenomics for BATF in a Pan-Cancer Cohort. Frontiers in Molecular Biosciences, 2022, 9, 844721.	1.6	1
617	Radiogenomics in Clear Cell Renal Cell Carcinoma: A Review of the Current Status and Future Directions. Cancers, 2022, 14, 2085.	1.7	7
618	Role of main RNA modifications in cancer: N6-methyladenosine, 5-methylcytosine, and pseudouridine. Signal Transduction and Targeted Therapy, 2022, 7, 142.	7.1	62
619	Molecular Subtypes Based on Genomic and Transcriptomic Features Correlate with the Responsiveness to Immune Checkpoint Inhibitors in Metastatic Clear Cell Renal Cell Carcinoma. Cancers, 2022, 14, 2354.	1.7	4
621	Deciphering radiological stable disease to immune checkpoint inhibitors. Annals of Oncology, 2022, 33, 824-835.	0.6	21
622	Exosomal PD-L1 predicts response with immunotherapy in NSCLC patients. Clinical and Experimental Immunology, 2022, 208, 316-322.	1.1	13
623	Construction of a Risk Model to Predict the Prognosis and Immunotherapy of Low-Grade Glioma Ground on 7 Ferroptosis-Related Genes. International Journal of General Medicine, 2022, Volume 15, 4697-4716.	0.8	3
624	Comprehensive Genomic Characterization of Tumor Microenvironment and Relevant Signature in Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2022, 12, .	1.3	0
625	A DNA Damage Repair Gene Signature Associated With Immunotherapy Response and Clinical Prognosis in Clear Cell Renal Cell Carcinoma. Frontiers in Genetics, 2022, 13, .	1.1	2
626	Role of SWI/SNF chromatin remodeling genes in lung cancer development. Biochemical Society Transactions, 2022, 50, 1143-1150.	1.6	6
627	Albendazole induces immunotherapy response by facilitating ubiquitin-mediated PD-L1 degradation. , 2022, 10, e003819.		13
628	Association of mutation with better clinical outcomes in pan-cancer for immune checkpoint inhibitors.. American Journal of Cancer Research, 2022, 12, 1766-1783.	1.4	0
630	mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers. Journal of Translational Medicine, 2022, 20, .	1.8	9
631	Necroptosis-Related LncRNAs Signature and Subtypes for Predicting Prognosis and Revealing the Immune Microenvironment in Breast Cancer. Frontiers in Oncology, 0, 12, .	1.3	2
632	Case Report: PTEN Mutation Induced by anti-PD-1 Therapy in Stage IV Lung Adenocarcinoma. Frontiers in Pharmacology, 0, 13, .	1.6	4
634	Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma. Genome Medicine, 2022, 14, .	3.6	24

#	ARTICLE	IF	CITATIONS
635	Precision Medicine in Cholangiocarcinoma: Past, Present, and Future. Life, 2022, 12, 829.	1.1	8
636	Tackling drug resistance in ovarian cancer with epigenetic targeted drugs. European Journal of Pharmacology, 2022, 927, 175071.	1.7	8
638	Potential prognosis index for m6A-related mRNA in cholangiocarcinoma. BMC Cancer, 2022, 22, .	1.1	4
639	Potential Application of Pyroptosis in Kidney Renal Clear Cell Carcinoma Immunotherapy and Targeted Therapy. Frontiers in Pharmacology, 0, 13, .	1.6	4
640	IGFBP7 and the Tumor Immune Landscape: A Novel Target for Immunotherapy in Bladder Cancer. Frontiers in Immunology, 0, 13, .	2.2	10
641	Emerging Biomaterials Imaging Antitumor Immune Response. Advanced Materials, 2022, 34, .	11.1	22
642	Computational Recognition of a Regulatory T-cell-specific Signature With Potential Implications in Prognosis, Immunotherapy, and Therapeutic Resistance of Prostate Cancer. Frontiers in Immunology, 0, 13, .	2.2	3
643	Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy. Journal of Clinical Investigation, 2022, 132, .	3.9	9
644	Comprehensive Evaluation of the m6A Regulator Prognostic Risk Score in the Prediction of Immunotherapy Response in Clear Cell Renal Cell Carcinoma. Frontiers in Immunology, 0, 13, .	2.2	5
645	Prevalence of SWI/SNF genomic alterations in cancer and association with the response to immune checkpoint inhibitors: A systematic review and meta-analysis. Gene, 2022, 834, 146638.	1.0	11
646	Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer. Nature Communications, 2022, 13, .	5.8	21
647	A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma. Nature Cancer, 2022, 3, 885-898.	5.7	20
648	Evaluation of Annexins Family as Potential Biomarker for Predicting Progression and Prognosis in Clear Renal Cell Carcinoma. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-13.	0.5	0
649	Identification and validation of co-expressed immune-related gene signature affecting the pattern of immune infiltrating in esophageal cancer. Combinatorial Chemistry and High Throughput Screening, 2022, 25, .	0.6	0
650	Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations. Scientific Reports, 2022, 12, .	1.6	2
651	Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer. Seminars in Oncology, 2022, 49, 306-318.	0.8	8
652	MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights. International Journal of Molecular Sciences, 2022, 23, 7649.	1.8	10
653	Microsatellite Instability–High Endometrial Cancers with <i>MLH1</i> Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles. Clinical Cancer Research, 2022, 28, 4302-4311.	3.2	14

#	Article	IF	Citations
654	To Identify Adenomatous Polyposis Coli Gene Mutation as a Predictive Marker of Endometrial Cancer Immunotherapy. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	1
655	Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal Cancer. Cancer Research Communications, 2022, 2, 894-903.	0.7	0
656	PBAF loss leads to DNA damage-induced inflammatory signaling through defective G2/M checkpoint maintenance. Genes and Development, 2022, 36, 790-806.	2.7	4
657	Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses. Journal of Clinical Investigation, 2022, 132, .	3.9	8
658	PANK1 associates with cancer metabolism and immune infiltration in clear cell renal cell carcinoma: a retrospective prognostic study based on the TCGA database. Translational Cancer Research, 2022, 11, 2321-2337.	0.4	1
659	Aging-based molecular classification and score system in ccRCC uncovers distinct prognosis, tumor immunogenicity, and treatment sensitivity. Frontiers in Immunology, 0, 13, .	2.2	0
660	Advances in Molecular Biological and Translational Studies in World Health Organization Grades 2 and 3 Meningiomas: A Literature Review. Neurologia Medico-Chirurgica, 2022, 62, 347-360.	1.0	4
661	A score of DNA damage repair pathway with the predictive ability for chemotherapy and immunotherapy is strongly associated with immune signaling pathway in pan-cancer. Frontiers in Immunology, 0, 13, .	2.2	6
662	IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma. Frontiers in Oncology, 0, 12, .	1.3	5
663	Homologous recombination repair gene mutations as a predictive biomarker for immunotherapy in patients with advanced melanoma. Frontiers in Immunology, 0, 13, .	2.2	8
664	An immunotherapy response prediction model derived from proliferative CD4+ T cells and antigen-presenting monocytes in ccRCC. Frontiers in Immunology, 0, 13, .	2.2	7
665	Identification of epigenetic dysregulation gene markers and immune landscape in kidney renal clear cell carcinoma by comprehensive genomic analysis. Frontiers in Immunology, 0, 13, .	2.2	3
666	Multiple primary malignancies with complex genomic profiling. Current Problems in Cancer Case Reports, 2022, 7, 100185.	0.1	0
667	Pan-cancer landscape of T-cell exhaustion heterogeneity within the tumor microenvironment revealed a progressive roadmap of hierarchical dysfunction associated with prognosis and therapeutic efficacy. EBioMedicine, 2022, 83, 104207.	2.7	43
668	Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial. Lancet Oncology, The, 2022, 23, 1287-1296.	5.1	18
669	Anti-neoplastic Immunomodulatory Treatments and the Pituitary. , 2022, , 309-320.		0
670	Current and future perspectives on CAR-T cell therapy for renal cell carcinoma: A comprehensive review. Investigative and Clinical Urology, 2022, 63, 486.	1.0	7
671	Leveraging big data of immune checkpoint blockade response identifies novel potential targets. Annals of Oncology, 2022, 33, 1304-1317.	0.6	20

#	Article	IF	Citations
672	A novel tumor mutation burden related lncRNA signature identified prognosis and tumor immune microenvironment features in clear cell renal cell carcinoma. Combinatorial Chemistry and High Throughput Screening, 2022, 25, .	0.6	0
673	Construction and Characterization of n6-Methyladenosine-Related lncRNA Prognostic Signature and Immune Cell Infiltration in Kidney Renal Clear Cell Carcinoma. Journal of Oncology, 2022, 2022, 1-10.	0.6	2
674	Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma. Clinical Cancer Research, 2022, 28, 4807-4819.	3.2	6
675	A radiogenomics biomarker based on immunological heterogeneity for non-invasive prognosis of renal clear cell carcinoma. Frontiers in Immunology, 0, 13, .	2.2	9
676	Development and validation of a novel cellular senescence-related prognostic signature for predicting the survival and immune landscape in hepatocellular carcinoma. Frontiers in Genetics, 0, 13, .	1.1	6
677	Chromatin remodeling (SWI/SNF) complexes, cancer, and response to immunotherapy. , 2022, 10, e004669.		7
678	SWI/SNF-deficient Malignancies: Optimal Candidates for Immune-oncological Therapy?. Advances in Anatomic Pathology, 0, Publish Ahead of Print, .	2.4	4
679	A signature based on chromatin regulation and tumor microenvironment infiltration in clear cell renal cell carcinoma. Epigenomics, 2022, 14, 995-1013.	1.0	0
680	Neoantigens and their clinical applications in human gastrointestinal cancers. World Journal of Surgical Oncology, 2022, 20, .	0.8	1
681	The convergence of tumor suppressors on interferon pathway in kidney cancer and its therapeutic implication. American Journal of Physiology - Cell Physiology, 0, , .	2.1	1
682	Clinical implications of the tumor microenvironment using multiplexed immunohistochemistry in patients with advanced or metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. Frontiers in Oncology, 0, 12, .	1.3	3
683	PBRM1 presents a potential prognostic marker and therapeutic target in duodenal papillary carcinoma. Clinical and Translational Medicine, 2022, 12, .	1.7	0
684	Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01). Journal of Clinical Oncology, 2023, 41, 651-663.	0.8	45
685	HIF1A predicts the efficacy of anti-PD-1 therapy in advanced clear cell renal cell carcinoma. Translational Oncology, 2022, 26, 101554.	1.7	2
686	Designer Microbes: Oncotherapy Approach. , 2022, , 231-247.		0
688	Advances in sex disparities for cancer immunotherapy: unveiling the dilemma of Yin and Yang. Biology of Sex Differences, 2022, 13, .	1.8	9
689	A predictive signature based on enhancer RNA associates with immune infiltration and aids treatment decision in clear cell renal cell carcinoma. Frontiers in Oncology, 0, 12, .	1.3	0
690	Selective and Cell-Active PBRM1 Bromodomain Inhibitors Discovered through NMR Fragment Screening. Journal of Medicinal Chemistry, 2022, 65, 13714-13735.	2.9	10

#	ARTICLE	IF	CITATIONS
691	Targeting Chromatin-Remodeling Factors in Cancer Cells: Promising Molecules in Cancer Therapy. International Journal of Molecular Sciences, 2022, 23, 12815.	1.8	4
692	MED12 mutation as a potential predictive biomarker for immune checkpoint inhibitors in pan-cancer. European Journal of Medical Research, 2022, 27, .	0.9	0
693	Subcellular location of source proteins improves prediction of neoantigens for immunotherapy. EMBO Journal, 2022, 41, .	3.5	2
694	Machine learning on syngeneic mouse tumor profiles to model clinical immunotherapy response. Science Advances, 2022, 8, .	4.7	6
696	Netie: inferring the evolution of neoantigen–T cell interactions in tumors. Nature Methods, 2022, 19, 1480-1489.	9.0	4
698	Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance. Frontiers in Oncology, 0, 12, .	1.3	8
699	The Inflammasomes Adaptor Protein PYCARD Is a Potential Pyroptosis Biomarker Related to Immune Response and Prognosis in Clear Cell Renal Cell Carcinoma. Cancers, 2022, 14, 4992.	1.7	3
700	Predicting prognosis and immunotherapeutic response of clear cell renal cell carcinoma. Frontiers in Pharmacology, 0, 13, .	1.6	2
701	PBRM1, SETD2 and BAP1 – the trinity of 3p in clear cell renal cell carcinoma. Nature Reviews Urology, 2023, 20, 96-115.	1.9	14
702	Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes. Clinical Cancer Research, 2023, 29, 261-270.	3.2	8
703	Roles of DNA damage repair and precise targeted therapy in renal cancer (Review). Oncology Reports, 2022, 48, .	1.2	3
704	Alternative Complement Pathway Signature Determines Immunosuppression and Resistance to Immunotherapy Plus Tyrosine Kinase Inhibitor Combinations in Renal Cell Carcinoma. Urologic Oncology: Seminars and Original Investigations, 2022, , .	0.8	3
705	SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 cases. Cancer Cell International, 2022, 22, .	1.8	7
706	A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma. Frontiers in Immunology, 0, 13, .	2.2	4
707	A CRISPR Path to Finding Vulnerabilities and Solving Drug Resistance: Targeting the Diverse Cancer Landscape and Its Ecosystem. Genetics & Genomics Next, 2022, 3, .	0.8	3
708	A chronicle review of new techniques that facilitate the understanding and development of optimal individualized therapeutic strategies for chordoma. Frontiers in Oncology, 0, 12, .	1.3	2
709	An ErbB Lineage Co-Regulon Harbors Potentially Co-Druggable Targets for Multimodal Precision Therapy in Head and Neck Squamous Cell Carcinoma. International Journal of Molecular Sciences, 2022, 23, 13497.	1.8	0
710	Intra-Tumor Cell Heterogeneity: Different Immune Responses for Different Cells. , 2022, , 1-26.		0

#	Article	IF	Citations
711	Current and Future Biomarkers in the Management of Renal Cell Carcinoma. Urologic Clinics of North America, 2023, 50, 151-159.	0.8	2
712	SMARCA4: Current status and future perspectives in non-small-cell lung cancer. Cancer Letters, 2023, 554, 216022.	3.2	14
713	A Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 Immunotherapy. Cancer Informatics, 2022, 21, 117693512211360.	0.9	1
714	Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer. Expert Review of Precision Medicine and Drug Development, 2022, 7, 131-149.	0.4	3
715	Cell Differentiation Trajectory Predicts Prognosis and Immunotherapeutic Response in Clear Cell Renal Cell Carcinoma. Genetical Research, 2022, 2022, 1-19.	0.3	1
716	Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. Nature Reviews Urology, 2023, 20, 133-157.	1.9	46
717	Renal Carcinoma and Angiogenesis: Therapeutic Target and Biomarkers of Response in Current Therapies. Cancers, 2022, 14, 6167.	1.7	9
718	Therapy sculpts the complex interplay between cancer and the immune system during tumour evolution. Genome Medicine, 2022, 14, .	3.6	15
719	ACAP1 Deficiency Predicts Inferior Immunotherapy Response in Solid Tumors. Cancers, 2022, 14, 5951.	1.7	4
721	Upregulation of CENPM is associated with poor clinical outcome and suppression of immune profile in clear cell renal cell carcinoma. Hereditas, 2023, 160, .	0.5	0
722	Non‐SMC condensin I complex subunit H participates in anti‐programmed cell death‐1 resistance of clear cell renal cell carcinomas. Cell Proliferation, 2023, 56, .	2.4	3
723	A Novel Four Mitochondrial Respiration-Related Signature for Predicting Biochemical Recurrence of Prostate Cancer. Journal of Clinical Medicine, 2023, 12, 654.	1.0	0
724	Caspase-8 contributes to an immuno-hot microenvironment by promoting phagocytosis via an ecto-calreticulin-dependent mechanism. Experimental Hematology and Oncology, 2023, 12, .	2.0	0
725	SPATS2 is correlated with cell cycle progression and immune cells infiltration in hepatocellular carcinoma. BMC Gastroenterology, 2023, 23, .	0.8	0
726	Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma. Nature Communications, 2023, 14, .	5.8	5
727	PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers. Frontiers in Genetics, 0, 13, .	1.1	4
728	MHC II immunogenicity shapes the neoepitope landscape in human tumors. Nature Genetics, 2023, 55, 221-231.	9.4	5
729	Genetic dysregulation of immunologic and oncogenic signaling pathways associated with tumor-intrinsic immune resistance: a molecular basis for combination targeted therapy-immunotherapy for cancer. Cellular and Molecular Life Sciences, 2023, 80, .	2.4	3

#	ARTICLE	IF	CITATIONS
730	YAP-Activated SATB2 Is a Coactivator of NRF2 That Amplifies Antioxidative Capacity and Promotes Tumor Progression in Renal Cell Carcinoma. Cancer Research, 2023, 83, 786-803.	0.4	1
731	Role of Gut Microbiome in Immune Regulation and Immune Checkpoint Therapy of Colorectal Cancer. Digestive Diseases and Sciences, 2023, 68, 370-379.	1.1	3
732	5-Methylcytosine (m5C) Modification Patterns and Tumor Immune Infiltration Characteristics in Clear Cell Renal Cell Carcinoma. Current Oncology, 2023, 30, 559-574.	0.9	2
734	Hypoxia signaling in cancer: Implications for therapeutic interventions. MedComm, 2023, 4, .	3.1	16
735	Identification of IRF-associated molecular subtypes in clear cell renal cell carcinoma to characterize immunological characteristics and guide therapy. Frontiers in Oncology, 0, 12, .	1.3	1
736	A 3D Ex Vivo Tumor–Immune Coculture System Mimicking In Vivo Tumor Environmental Stress on CD8+ T Cells Exhaustion. Advanced Biology, 2023, 7, .	1.4	1
737	Current advances in immunotherapy for atypical teratoid rhabdoid tumor (ATRT). Neuro-Oncology Practice, 2023, 10, 322-334.	1.0	3
738	Viewing RCC with a DNA methylation lens ENHANCES understanding of ICI resistance. Clinical Cancer Research, 0, , .	3.2	0
739	Adaptive Immunity in Genitourinary Cancers. European Urology Oncology, 2023, 6, 263-272.	2.6	3
740	Exploration of 68Ga-labelled prostate-specific membrane antigen-11 PET/CT parameters for identifying PBRM1 status in primary clear cell renal cell carcinoma. Clinical Radiology, 2023, 78, e417-e424.	0.5	1
741	Checkpoint Blockade in Hematologic Malignancies. , 2022, , 1-42.		0
742	Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit. Communications Medicine, 2023, 3, .	1.9	9
743	EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1. Advanced Science, 2023, 10, .	5.6	5
745	Fat Loss in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 2023, 24, 3994.	1.8	0
746	Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma. Cell Reports Medicine, 2023, 4, 100947.	3.3	7
747	Metabolic classifications of renal cell carcinoma reveal intrinsic connections with clinical and immune characteristics. Journal of Translational Medicine, 2023, 21, .	1.8	2
748	SWI/SNF Complex Genomic Alterations as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Multiple Cancers. Cancer Immunology Research, 2023, 11, 646-656.	1.6	7
749	Renal Cell Carcinomas. , 2023, , 337-355.		0

#	ARTICLE	IF	CITATIONS
750	Single-Cell and Transcriptome-Based Immune Cell-Related Prognostic Model in Clear Cell Renal Cell Carcinoma. Journal of Oncology, 2023, 2023, 1-15.	0.6	0
751	Pan-cancer analysis reveals signal transducer and activator of transcription (STAT) gene family as biomarkers for prognostic prediction and therapeutic guidance. Frontiers in Genetics, 0, 14, .	1.1	0
753	High GTSE1 expression promotes cell proliferation, metastasis and cisplatin resistance in ccRCC and is associated with immune infiltrates and poor prognosis. Frontiers in Genetics, 0, 14, .	1.1	0
754	Advanced CT Imaging, Radiomics, and Artificial Intelligence to Evaluate Immune Checkpoint Inhibitors' Effects on Metastatic Renal Cell Carcinoma. Applied Sciences (Switzerland), 2023, 13, 3779.	1.3	1
755	An immune infiltration-related prognostic model of kidney renal clear cell carcinoma with two valuable markers: CAPN12 and MSC. Frontiers in Oncology, 0, 13, .	1.3	0
759	Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis. Cancer Cell, 2023, 41, 740-756.e10.	7.7	10
760	Immune Checkpoint Blockade Response Biomarkers. , 2023, , 1-34.		0
761	Immunogenicity in renal cell carcinoma: shifting focus to alternative sources of tumour-specific antigens. Nature Reviews Nephrology, 2023, 19, 440-450.	4.1	4
762	Development and validation of a novel defined mutation classifier based on Lasso logistic regression for predicting the overall survival of immune checkpoint inhibitor therapy in renal cell carcinoma. Translational Andrology and Urology, 2023, 12, 406-424.	0.6	0
763	An immune-related prognostic model predicts neoplasm-immunity interactions for metastatic nasopharyngeal carcinoma. Frontiers in Immunology, 0, 14, .	2.2	2
764	NDC80 status pinpoints mitotic kinase inhibitors as emerging therapeutic options in clear cell renal cell carcinoma. IScience, 2023, 26, 106531.	1.9	0
765	Targeting of the SWI/SNF chromatin remodeling complex in cancer therapy. Uspehi Molekularnoj Onkologii, 2023, 10, 8-17.	0.1	0
766	BAP1-related signature predicts benefits from immunotherapy over VEGFR/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN Renal 101 and checkmate-009/010/025 trials. Cancer Immunology, Immunotherapy, 2023, 72, 2557-2572.	2.0	2
767	Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors. Acta Pharmacologica Sinica, 2023, 44, 1879-1889.	2.8	15
768	Development and validation of a novel 5 cuproptosis-related long noncoding RNA signature to predict diagnosis, prognosis, and drug therapy in clear cell renal cell carcinoma. Translational Andrology and Urology, 2023, .	0.6	1
769	Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma. European Urology, 2023, 84, 166-175.	0.9	7
770	Radiogenomic Associations Clear Cell Renal Cell Carcinoma: An Exploratory Study. Oncology, 2023, 101, 375-388.	0.9	1
796	The PD-1 single-nucleotide polymorphism rs11568821 and rs2227981 as a novel prognosis model in a triple-negative breast cancer patient. Molecular Biology Reports, 2023, 50, 6279-6285.	1.0	3

#	ARTICLE	IF	CITATIONS
829	The bromodomain acyl-lysine readers in human health and disease. , 2024, , 57-97.		0
837	Context-specific functions of chromatin remodellers in development and disease. Nature Reviews Genetics, 0, , .	7.7	3
840	Predictive Biomarkers in Advanced Renal Cell Carcinoma. , 2023, , 251-268.		0
841	Prognostic Factors in Advanced Renal Cell Carcinoma. , 2023, , 233-250.		0
856	Current status and future perspective of immunotherapy for renal cell carcinoma. International Journal of Clinical Oncology, 0, , .	1.0	0
875	Role of biomarkers in assessing response to immune checkpoint inhibitors in cancer treatment. , 2024, , 281-303.		0
894	Nierenzellkarzinome. , 2024, , 387-408.		0